| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3 … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... The Lancet 376 (9742), 687-697, 2010 | 7816 | 2010 |
| Gastric cancer EC Smyth, M Nilsson, HI Grabsch, NCT van Grieken, F Lordick The Lancet 396 (10251), 635-648, 2020 | 2619 | 2020 |
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with … M Peeters, T Jay Price JOURNAL OF CLINICAL ONCOLOGY, 2010 | 1243 | 2010 |
| Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial G Folprecht, T Gruenberger, WO Bechstein, HR Raab, F Lordick, ... The lancet oncology 11 (1), 38-47, 2010 | 1212 | 2010 |
| Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up F Lordick, C Mariette, K Haustermans, R Obermannová, D Arnold Annals of Oncology 27, v50-v57, 2016 | 971 | 2016 |
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial F Lordick, YK Kang, HC Chung, P Salman, SC Oh, G Bodoky, G Kurteva, ... The lancet oncology 14 (6), 490-499, 2013 | 947 | 2013 |
| PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial F Lordick, K Ott, BJ Krause, WA Weber, K Becker, HJ Stein, S Lorenzen, ... The lancet oncology 8 (9), 797-805, 2007 | 945 | 2007 |
| Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer … C Schuhmacher, S Gretschel, F Lordick, P Reichardt, W Hohenberger, ... Journal of clinical oncology 28 (35), 5210, 2010 | 853 | 2010 |
| Oesophageal cancer EC Smyth, J Lagergren, RC Fitzgerald, F Lordick, MA Shah, P Lagergren, ... Nature reviews Disease primers 3 (1), 1-21, 2017 | 847 | 2017 |
| Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer T Kojima, MA Shah, K Muro, E Francois, A Adenis, CH Hsu, T Doi, ... Journal of Clinical Oncology 38 (35), 4138-4148, 2020 | 706 | 2020 |
| Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter … H Yang, H Liu, Y Chen, C Zhu, W Fang, Z Yu, W Mao, J Xiang, Y Han, ... Journal of Clinical Oncology 36 (27), 2796, 2018 | 677 | 2018 |
| Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment HA Wieder, BLDM Brucher, F Zimmermann, K Becker, F Lordick, A Beer, ... Journal of Clinical Oncology 22 (5), 900-908, 2004 | 576 | 2004 |
| Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction K Ott, WA Weber, F Lordick, K Becker, R Busch, K Herrmann, H Wieder, ... Journal of clinical oncology 24 (29), 4692-4698, 2006 | 564 | 2006 |
| A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic … MS Aapro, SM Grunberg, GM Manikhas, G Olivares, T Suarez, ... Annals of oncology 17 (9), 1441-1449, 2006 | 444 | 2006 |
| Efficacy and safety of pembrolizumab for heavily pretreated patients with advanced, metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: the phase 2 KEYNOTE … MA Shah, T Kojima, D Hochhauser, P Enzinger, J Raimbourg, ... JAMA oncology 5 (4), 546-550, 2019 | 438 | 2019 |
| Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆ F Lordick, F Carneiro, S Cascinu, T Fleitas, K Haustermans, G Piessen, ... Annals of Oncology 33 (10), 1005-1020, 2022 | 427 | 2022 |
| Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial K Ott, U Fink, K Becker, A Stahl, HJ Dittler, R Busch, H Stein, F Lordick, ... Journal of clinical oncology 21 (24), 4604-4610, 2003 | 418 | 2003 |
| Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer E Van Cutsem, Y Kang, H Chung, L Shen, A Sawaki, F Lordick, J Hill, ... J clin oncol 27 (18), LBA4509, 2009 | 408 | 2009 |
| ToGA Trial Investigators: Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction … YJ Bang, E Van Cutsem, A Feyereislova, HC Chung, L Shen, A Sawaki, ... Lancet 376 (9742), 687-697, 2010 | 353 | 2010 |
| ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in … J Hoeppner, F Lordick, T Brunner, T Glatz, P Bronsert, N Röthling, ... BMC cancer 16, 1-10, 2016 | 309 | 2016 |
Yung-Jue BangProfessorПідтверджена електронна адреса в boconsulting.io
